Related Experiment Videos
Neovascularisation offers a new perspective to glutamine related therapy
P Maity1, S Chakraborty, P Bhattacharya
1Department of Metabolic Regulation, Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Road, Calcutta-700 026, India.
Abstract:
Angiogenesis or the generation of new blood vessel, is an important factor in the growth of a solid tumor. Hence, it becomes a necessary parameter of any kind of therapeutic study. Glutamine is an essential nutrient of tumor tissue and glutamine related therapy involves clearance of circulatory glutamine by glutaminase. Therefore, using different murine solid tumor models, the present study was undertaken to find out whether the S-180 cell glutaminase has any effect on angiogenesis of solid tumor, or not. Result indicates that the purified S-180 cell glutaminase reduces tumor volume and restrict the generation of neo blood vessels. Therefore, it can be concluded that this enzyme may be an effective device against the cancer metastasis.
Insights
This study investigated S-180 cell glutaminase
Area of Science:
- Oncology
- Biochemistry
- Molecular Biology
Background:
- Tumor growth relies on angiogenesis (new blood vessel formation).
- Glutamine is a vital nutrient for tumor cells.
- Glutamine-targeting therapies use glutaminase to deplete this nutrient.
Purpose of the Study:
- To determine if S-180 cell glutaminase impacts solid tumor angiogenesis.
- To explore the therapeutic potential of S-180 cell glutaminase in cancer treatment.
Main Methods:
- Utilized various murine solid tumor models.
- Administered purified S-180 cell glutaminase.
Main Results:
- S-180 cell glutaminase significantly reduced tumor volume.
- The enzyme inhibited the formation of new blood vessels (angiogenesis) within tumors.
Conclusions:
- S-180 cell glutaminase demonstrates anti-tumor effects by inhibiting angiogenesis.
- This enzyme shows promise as a therapeutic agent against cancer metastasis.